Vital Farms, Inc. Q3 FY2026 earnings call

• Market Normalization & Pricing: Avian influenza-induced supply constraints have ended, causing conventional egg prices to drop to pre-crisis levels (~$2/dozen). The price gap between Vital Farms and private label has returned to mid-2023 norms.
• Consumer Behavior Shift: The primary driver of performance decline is 'light buyers' trading back to private label after being attracted by compressed price gaps during the avian influenza crisis. Volume loss is attributed to this churn rather than increased branded competition.
• Supply Management: Farmer contract amendments are in place, allowing better supply control. Volume sent to breaker and wholesale channels fell 59% sequentially from Q2, which was the key driver for margin recovery.
• Distribution Milestones: Achieved record dollar share (7.2%) and volume share (2.3%) in Circana MULO+ at end of Q3. Average Shell Egg TDPs reached 176 in late October, exceeding the full-year average of 152.
• Cost Efficiency: Successfully reduced annualized SG&A run rate by approximately $6–7 million through efficiency actions. Capital expenditures for the Vital Crossroads project are paused after enclosure, reducing expected annual CapEx to $70–75 million.
• Strategic Pivot: Withdrawal of 2030 financial targets to focus on near-term execution and profitability improvement. Long-term view remains positive as pasture-raised household penetration has doubled since 2022.

Net revenue was $182.2 million, representing a 10% sequential increase from Q2 but an 8.4% year-over-year decline. Gross profit totaled $42.1 million with a 23.1% margin, up more than 16 percentage points sequentially due to reduced breaker/wholesale volume and improved retail mix. Adjusted EBITDA improved significantly to $1.5 million from a $26.6 million loss in Q2. SG&A expenses were $38.1 million, down 14% year-over-year.

• Full-Year Net Sales: Reduced to approximately $730 million, down from the previous outlook of $775–800 million.
• Full-Year Adjusted EBITDA: Lowered to approximately negative $15 million, revised from a previous expectation of $0–10 million gain.
• Q4 Revenue Drivers: Guidance reflects three conservative assumptions: lack of typical seasonal demand uptick, delayed new distribution placements reducing selling weeks, and no assumption of seasonal pricing firming in conventional eggs.
• Q4 Operational Assumptions: Assumes shell egg unit velocity of ~25.9 EQ units/store/week/item; assumes promotional activity continues but velocity contribution from new distribution is slower than planned; expects $3–4 million from butter sales clearing remaining inventory.

• Transitory Growth: Risk that growth driven by temporary market distortions (avian influenza) may not be enduring, leading to lower baseline performance as normalcy returns.
• Seasonality Disruption: Deviation from historical seasonal patterns in consumer behavior and retailer inventory management could negatively impact Q4 results.
• Supply Chain Execution: Delays in new distribution placements highlight logistical challenges that can compress selling windows and delay revenue recognition.
• Commodity Volatility: Exposure to fluctuations in fuel rates, line haul rates, and potential future avian influenza outbreaks affecting industry supply and pricing dynamics.

Q: Analyst asked about the shift in pricing strategy given light buyers returning to private label instead of other brands.

A: CEO explained that their price multiple to private label is now back to mid-2023 levels, confirming their pricing isn't excessively high. The volume loss is largely due to trial households reverting to private label post-bird flu, not brand poaching. Consequently, they are returning to a 'normal' strategy focused on smart promotional investments for trial rather than aggressively narrowing price gaps with competitors.

Q: Analyst asked why new distribution wins arrived later than expected and how this impacts cadence.

A: CEO attributed the delays to logistical challenges in executing large-scale placements across varied stores, noting it was a supply chain execution issue rather than a strategic failure. He advised investors to be conservative regarding the timing of new committed distribution going forward, though all targeted shelves are now active.

Q: Analyst asked about the breakdown of the guidance revision and thoughts on innovation in the free-range category.

A: CFO stated the $55M revenue reduction stems from three Q4 factors: missing seasonal demand upticks, no seasonal pricing recovery, and delayed distribution. Russell Diez-Canseco added that they are piloting a free-range egg product to raise standards in that segment and reach households buying below $5/dozen, aiming to expand beyond their current 2.3% volume share.

Q: Analyst asked about the capacity and operations at the Eastern Corn States (ECS) facility and farmer rightsizing efforts.

A: CEO reported excellent uptime and fill rates at ECS with its third line, noting run-rate capacity is approaching $1 billion. Regarding farmers, he emphasized strong partnerships where they honored commitments despite needing less supply, contrasting with industry norms. Contract amendments allow them to adjust flock lengths, aligning supply much closer to demand than in Q2.

Q: Analyst asked how the company will maintain flexibility for next year's easy compares and capitalize on potential supply contractions.

A: CEO stated they will be cautious about adding capacity based on transient growth sources, focusing instead on enduring brand strength. He clarified that farmer amendments are reversible options, not permanent cuts, allowing rapid repopulation if needed. However, he cautioned against speculating on upside from bird flu events, noting any benefits would be muted compared to conventional producers.